Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer.
AffiliationDepartment of Clinical Oncology, Christie Hospital, Manchester, United Kingdom.
MetadataShow full item record
AbstractPURPOSE: Patients with ovarian cancer often experience dose-limiting myelotoxicity, nephrotoxicity and anemia following treatment with platinum-based chemotherapy. PATIENTS AND METHODS: To investigate the ability of recombinant human erythropoietin (epoetin alfa) to prevent the development of anemia, 30 patients with advanced ovarian carcinoma receiving cisplatin or carboplatin were randomly assigned to treatment with subcutaneous epoetin alfa 300 IU/kg three times a week in addition to conventional supportive treatment, or conventional supportive treatment alone, for up to six chemotherapy cycles. The dose of epoetin alfa was reduced if hemoglobin concentration exceeded 15 g/dL. RESULTS: A highly significant difference in mean hemoglobin concentrations was observed between the two groups during the first cycle of chemotherapy due to a significant decrease in mean hemoglobin concentration in the control group. A maximal difference of 3.4 g/dL was achieved during cycle three. Fewer patients required blood or platelet transfusions in the epoetin alfa-treated group, although the difference was not significant compared to the control group. Epoetin alfa was well tolerated. CONCLUSION: Epoetin alfa appears to be effective and well tolerated in preventing hemoglobin decline in patients undergoing aggressive cyclic platinum-based chemotherapy for advanced ovarian carcinoma.
CitationRecombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer., 1 (4):261-6 Cancer J Sci Am
JournalThe Cancer Journal from Scientific American
- Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer.
- Authors: Thatcher N, De Campos ES, Bell DR, Steward WP, Varghese G, Morant R, Vansteenkiste JF, Rosso R, Ewers SB, Sundal E, Schatzmann E, Stocker H
- Issue date: 1999 May
- Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
- Authors: Voravud N, Sriuranpong V, Suwanrusme H
- Issue date: 2007 Jun
- A new induction schedule of epoetin alfa 40.000 IU in anemic patients with advanced lung cancer.
- Authors: Ariganello O, Mancuso A, Di Molfetta M, Diana F, Beccaglia P, Cortesi E, De Marinis F
- Issue date: 2004 Oct
- Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy.
- Authors: Chang J, Couture F, Young S, McWatters KL, Lau CY
- Issue date: 2005 Apr 20
- Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
- Authors: Patton J, Kuzur M, Liggett W, Miranda F, Varsos H, Porter L
- Issue date: 2004